SCHEMBL2686712

SCHEMBL2686712

Cc1cc(-c2cnc(OCC(=O)O)c(NC(=O)[C@@H](N)Cc3ccccc3)c2)ccn1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GPR142 Q7Z601 7/20 0.47
▸ WNT3A P56704 3/20 0.43
▸ PIK3CD O00329 1/20 0.42
▸ PIK3CA P42336 1/20 0.42
▸ PIK3CB P42338 1/20 0.42
▸ PIK3CG P48736 1/20 0.42
▸ CIT O14578 1/20 0.42
▸ MAPK1 P28482 2/20 0.41
▸ PSEN1 P49768 1/20 0.40
▸ PSEN2 P49810 1/20 0.40
▸ APH1B Q8WW43 1/20 0.40
▸ NCSTN Q92542 1/20 0.40
▸ APH1A Q96BI3 1/20 0.40
▸ PSENEN Q9NZ42 1/20 0.40
▸ CDK2 P24941 2/20 0.40
▸ CDK7 P50613 2/20 0.40
▸ LNPEP Q9UIQ6 1/20 0.40
▸ ROCK2 O75116 1/20 0.40
▸ ROCK1 Q13464 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2686723 1.00 GPR142 (0.47) GPR142WNT3APIK3CDPIK3CAPIK3CB
SCHEMBL2684336 0.91 GPR142 (0.53) GPR142WNT3APIK3CDPIK3CAPIK3CB
SCHEMBL6032434 0.90 GPR142 (0.44) GPR142WNT3APIK3CDPIK3CAPIK3CB
SCHEMBL15875890 0.90 GPR142 (0.44) GPR142WNT3APIK3CDPIK3CAPIK3CB
SCHEMBL2685807 0.86 PKM (0.42) GPR142WNT3AMAPK1PSEN1PSEN2
SCHEMBL2685802 0.86 PKM (0.42) GPR142WNT3AMAPK1PSEN1PSEN2
SCHEMBL2685260 0.83 GPR142 (0.53) GPR142WNT3ACITPSEN1PSEN2
SCHEMBL2683720 0.81 GPR142 (0.71) GPR142
SCHEMBL2683725 0.81 GPR142 (0.71) GPR142
SCHEMBL2685002 0.76 GPR142 (0.51) GPR142WNT3ACITPSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 — — US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 — — US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A GPR142 2779/4885WNT3A 4600/4885PIK3CD 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback